Second-Line Therapy Options in Metastatic Castration-Resistant Prostate Cancer
Robert Dreicer, MD, discusses the available second-line therapy options and unmet needs in metastatic castration-resistant prostate cancer.
Robert Dreicer, MD, discusses the available second-line therapy options and unmet needs in metastatic castration-resistant prostate cancer.
All patients have been successfully dosed in the first cohort of patients, and the Safety Review Committee has granted approval for progression of the study…
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Jaideep S. Sohi, MD, shares his vision for the future of PSMA-PET imaging in prostate cancer.
“There is great interest in looking at all these targeted interventions in the earlier stages to lower the burden of care that patients go through…
“The results showed the contemporary Aquablation procedural safety in Japanese men is exceptional in a broad range of prostate sizes along with significant symptom reduction,”…
“This was a very special moment, delivering the news to this patient that his cancer is now undetectable following the treatment with 2 doses of…
A late phase 3 trial evaluating the agent is underway at several clinics in Europe.
“This clinical study has the potential to demonstrate the value of Chimeric Antigen Receptor (CAR) T cell therapy in solid cancers such as kidney cancer…
“It’s a system that is still not being used to its maximum capability, which is exciting. That means we can continue evolving,” says Jaschar Shakuri-Rad,…
The first patient was treated with TLX250-CDx at the Olivia Newton-John Cancer Wellness Centre at Austin Health in Melbourne, Australia,